Authors:
Scapin, G
Patel, S
Patel, V
Kennedy, B
Asante-Appiah, E
Citation: G. Scapin et al., The structure of apo protein-tyrosine phosphatase 1B C215S mutant: More than just an S -> O change, PROTEIN SCI, 10(8), 2001, pp. 1596-1605
Authors:
Huffine, E
Crews, J
Kennedy, B
Bomberger, K
Zinbo, A
Citation: E. Huffine et al., Mass identification of persons missing from the break-up of the former Yugoslavia: Structure, function, and role of the International Commission on Missing Persons, CROAT MED J, 42(3), 2001, pp. 271-275
Authors:
Rawstron, AC
Kennedy, B
Evans, PAS
Davies, FE
Richards, SJ
Haynes, AP
Russell, NH
Hale, G
Morgan, GJ
Jack, AS
Hillmen, P
Citation: Ac. Rawstron et al., Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome andcan be used to optimize therapy, BLOOD, 98(1), 2001, pp. 29-35
Citation: B. Kennedy et Mg. Ziegler, Ontogeny of epinephrine metabolic pathways in the rat: role of glucocorticoids, INT J DEV N, 18(1), 2000, pp. 53-59
Authors:
Mills, PJ
Maisel, AS
Ziegler, MG
Dimsdale, JE
Carter, S
Kennedy, B
Woods, VL
Citation: Pj. Mills et al., Peripheral blood mononuclear cell-endothelial adhesion in human hypertension following exercise, J HYPERTENS, 18(12), 2000, pp. 1801-1806
Authors:
Gonzalez-Trapaga, JL
Nelesen, RA
Dimsdale, JE
Mills, PJ
Kennedy, B
Parmer, RJ
Ziegler, MG
Citation: Jl. Gonzalez-trapaga et al., Plasma epinephrine levels in hypertension and across gender and ethnicity, LIFE SCI, 66(24), 2000, pp. 2383-2392
Authors:
Norreys, PA
Santala, M
Clark, E
Zepf, M
Watts, I
Beg, FN
Krushelnick, K
Tatarakis, M
Dangor, AE
Fang, X
Graham, P
McCanny, T
Singhal, RP
Ledingham, KWD
Creswell, A
Sanderson, DCW
Magill, J
Machacek, A
Wark, JS
Allott, R
Kennedy, B
Neely, D
Citation: Pa. Norreys et al., Observation of a highly directional gamma-ray beam from ultrashort, ultraintense laser pulse interactions with solids, PHYS PLASMA, 6(5), 1999, pp. 2150-2156
Authors:
Prasit, P
Wang, Z
Brideau, C
Chan, CC
Charleson, S
Cromlish, W
Ethier, D
Evans, JF
Ford-Hutchinson, AW
Gauthier, JY
Gordon, R
Guay, J
Gresser, M
Kargman, S
Kennedy, B
Leblanc, Y
Leger, S
Mancini, J
O'Neill, GP
Ouellet, M
Percival, MD
Perrier, H
Riendeau, D
Rodger, I
Tagari, P
Therien, M
Vickers, P
Wong, E
Xu, LJ
Young, RN
Zamboni, R
Boyce, S
Rupniak, N
Forrest, N
Visco, D
Patrick, D
Citation: P. Prasit et al., The discovery of rofecoxib, [MK 966, Vioxx (R), 4-(4 '-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor, BIOORG MED, 9(13), 1999, pp. 1773-1778
Citation: G. Pratt et al., Cyclosporin neurotoxicity after chemotherapy - Case had features of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome, BR MED J, 319(7201), 1999, pp. 54-54
Authors:
Merrigan, D
Healton, C
Essien, JDK
Nelson, JC
Prothrow-Stith, D
Kennedy, B
Lawrence, R
Hart, DR
Banks, FR
Willis, WO
Wright, K
Anderson, A
Conway, JB
Maetz, M
Satariano, W
Kar, S
Citation: D. Merrigan et al., Where we stand, PUBL HEA RE, 114(2), 1999, pp. 194-197
Authors:
Chan, CC
Boyce, S
Brideau, C
Charleson, S
Cromlish, W
Ethier, D
Evans, J
Ford-Hutchinson, AW
Forrest, MJ
Gauthier, JY
Gordon, R
Gresser, M
Guay, J
Kargman, S
Kennedy, B
Leblanc, Y
Leger, S
Mancini, J
O'Neill, GP
Ouellet, M
Patrick, D
Percival, MD
Perrier, H
Prasit, P
Rodger, I
Tagari, P
Therien, M
Vickers, P
Visco, D
Wang, Z
Webb, J
Wong, E
Xu, LJ
Young, RN
Zamboni, R
Riendeau, D
Citation: Cc. Chan et al., Rofecoxib [Vioxx, MK-0966; 4-(4 '-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: A potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles, J PHARM EXP, 290(2), 1999, pp. 551-560